| 000 -LEADER |
|---|
| fixed length control field |
04611nam a22005295i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
978-1-59745-337-0 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20161121230841.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
100301s2008 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781597453370 |
| -- |
978-1-59745-337-0 |
| 024 7# - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1007/978-1-59745-337-0 |
| Source of number or code |
doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MJCL |
| Source |
bicssc |
| 072 #7 - SUBJECT CATEGORY CODE |
|---|
| Subject category code |
MED062000 |
| Source |
bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
614.5999 |
| Edition number |
23 |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Molecular Targeting in Oncology |
| Medium |
[electronic resource] / |
| Statement of responsibility, etc. |
edited by Howard L. Kaufman, Scott Wadler, Karen Antman. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Totowa, NJ : |
| Name of producer, publisher, distributor, manufacturer |
Humana Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XVI, 728 p. |
| Other physical details |
online resource. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
text file |
| Encoding format |
PDF |
| Source |
rda |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
General Strategies for Molecular Targeting in Oncology -- The Cell Cycle -- mTOR -- Ras/Raf/MEK Inhibitors -- 17-AAG -- The Cancer Epigenome -- Molecular Targeting for Specific Disease Sites -- Molecular Targeting in Upper Gastrointestinal Malignancies -- Molecular Targeting of Colorectal Cancer -- Molecular Targeting in Hepatocellular Carcinoma -- Molecularly Targeted Therapy in Pancreatic Cancer -- Untargeted Use of Targeted Therapy -- Renal Cell Carcinoma -- Targeted Therapies for Prostate Cancer -- Molecular Targets in Ovarian Cancer and Endometrial Cancer -- Targeted Therapy For Breast Cancer -- Melanoma -- Classes of Drugs for Molecular Targeting in Oncology -- Antibody Therapy of Cancer -- Nucleic Acid Therapies for Cancer Treatment -- Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy -- Vaccines as Targeted Cancer Therapy -- Cytokine-Based Therapy for Cancer -- Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment -- Specific Drugs for Molecular Targeting in Oncology -- Imatinib Mesylate (Gleevec�) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations -- Development of a Targeted Treatment for Cancer -- VEGF Inhibition for Cancer Therapy -- Somatostatin Analogue Therapy -- Challenges in Molecular Targeting in Oncology -- Patient Selection for Rational Development of Novel Anticancer Agents -- Clinical Trial Design with Targeted Agents -- How to Define Treatment Success or Failure if Tumors Do Not Shrink -- Molecular Imaging in Oncology -- Combinations of Molecular-Targeted Therapies -- Preclinical Development of Molecularly Targeted Agents in Oncology. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
In Molecular Targeting in Oncology, authors present an overview of the development of targeted therapies for the treatment of cancer with an emphasis on clinical application. The volume covers the complexity of the rapidly developing area of targeted therapies for the treatment of patients with cancer and is structured in a way so readers may begin with chapters that most interest them and work through the rest of the chapters in the order of their choice. The volume is divided into five sections that cover the most important elements of drug development. The first section focuses on approaches using targeted therapies to inhibit cell growth. The second section describes how clinicians are evaluating targeted therapies in specific organ systems. The third section illustrates how various classes of pharmacologic and immunologic agents are developed for individual molecular targets. The fourth section details new drugs that have novel mechanisms of action. The final section looks to the future of targeted therapeutics and includes chapters on appropriate patient selection, use of combination therapy, dealing with tumor cell resistance, and more. Comprehensive and cutting-edge, Molecular Targeting in Oncology is an essential reference for those working in the field. |
| 650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicine. |
| 650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer research. |
| 650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology. |
| 650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicinal chemistry. |
| 650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology.1 |
| 650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biomedicine.2 |
| 650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer Research.2 |
| 650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Oncology.2 |
| 650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pharmacology/Toxicology.2 |
| 650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicinal Chemistry.1 |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kaufman, Howard L. |
| Relator term |
editor.1 |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Wadler, Scott. |
| Relator term |
editor.1 |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Antman, Karen. |
| Relator term |
editor.2 |
| 710 ## - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service)0 |
| 773 ## - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks0 |
| 776 8# - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Relationship information |
Printed edition: |
| International Standard Book Number |
9781588295774 |
| 830 0# - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Cancer Drug Discovery and Development4 |
| 856 0# - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-59745-337-0 |
| 912 ## - |
|---|
| -- |
ZDB-2-SME |
